Plasma neurofilament light protein is differentially associated with age in individuals with treatment-resistant schizophrenia and bipolar affective disorder compared to controls

Cassandra MJ Wannan; Dhamidhu Eratne; Alexander F Santillo; Charles Malpas; Brandon Cilia; Olivia M Dean; Adam Walker; Michael Berk; Chad Bousman; Ian Everall; Dennis Velakoulis; Christos Pantelis

Journal article

Plasma neurofilament light protein is differentially associated with age in individuals with treatment-resistant schizophrenia and bipolar affective disorder compared to controls

Cassandra MJ Wannan, Dhamidhu Eratne, Alexander F Santillo, Charles Malpas, Brandon Cilia, Olivia M Dean, Adam Walker, Michael Berk, Chad Bousman, Ian Everall, Dennis Velakoulis, Christos Pantelis

Psychiatry Research | Elsevier | Published : 2024

DOI: 10.1016/j.psychres.2024.116073

Abstract

Accelerated brain ageing has been observed in multiple psychiatric disorders. This study examined whether relationships between age and plasma neurofilament light (NfL) protein differed in individuals with psychiatric disorders (major depressive disorder (n = 42), bipolar affective disorder (n = 121), treatment-resistant schizophrenia (TRS, n = 82)) compared to two healthy control (HC) groups (n = 1,926 and n = 59). Compared to two independent HC samples, individuals with TRS demonstrated a stronger positive relationship between age and NfL levels. Individuals with BPAD had a stronger negative relationship between age and NfL levels compared to the large normative HC cohort, but not locally-..

View full abstract

University of Melbourne Researchers

Cassandra Wannan Author

Dhamidhu Eratne Author

Charles Malpas Author

Michael Berk Author

Related Projects (2)

CREDIT: THE CRE FOR THE DEVELOPMENT OF INNOVATIVE THERAPIES FOR PSYCHIATRIC DISORDERS

NEUROBIOLOGICAL 'RISK' AND 'RESILIENCE' BIOMARKERS OF SEVERE MENTAL ILLNESS

Mental disorders of childhood (schizotypal disorder, autism spectrum disorders) and adolescence (psychoses, schizophrenia) represent a major..

Grants

Awarded by NHMRC Senior Principal Research Fellowship and Leadership 3 Investigator

Awarded by NHMRC CRE

Awarded by National Health and Medical Research Council (NHMRC) Senior Principal Research Fellow-ship

Awarded by NHMRC L3 Investigator Grant

Awarded by MACH MRFF RART 2.2, NHMRC

Funding Acknowledgements

MB is supported by a NHMRC Senior Principal Research Fellowship and Leadership 3 Investigator grant (1156072 and 2017131) . A.J.W. was supported by a Trisno Family Fellowship, funded in part by an NHMRC CRE (1153607) . C.P. was supported by a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellowship (1105825) , an NHMRC L3 Investigator Grant (1196508) . This study was also supported by MACH MRFF RART 2.2, NHMRC (1185180) , and Psychiatry and Rehabilitation Division, Region Sk.ne, Sweden. The role of these funding sources was to support research study staff and bio-sample analyses.